Cas9 Stable Cell Line - Jurkat

Jurkat cells, derived from the peripheral blood of a 14-year-old patient with T-cell acute lymphoblastic leukemia (T-ALL), are a well-known human T lymphocyte cell line commonly used in cell biology research, particularly in cancer research and immune system disorder investigations. Jurkat cells produce interleukin-2 and are used in research involving cancer's sensitivity to drugs and radiation. Jurkat cells are commonly used in HIV research because they express CD4 receptors on their cell membranes. The CD4 receptor is the primary receptor used by HIV to enter host cells. Because Jurkat cells express this receptor, they can be infected by HIV, making them a useful model for studying HIV's interaction with human T cells, the virus's primary target in the body. The use of Jurkat cells in studies of HIV activation and the life cycle of HIV infection has greatly contributed to the understanding of viral interactions with human cells and helped to identify potential targets for antiretroviral therapy.

Cas9 Stable Cell Line-Jurkat is a cell line that has been genetically engineered to stably express Cas9 endonuclease. The enzyme is a key component of the CRISPR/Cas9 system, a widely used genome-editing tool that allows genes to be added, deleted or changed within an organism's cells. The use of stable cell lines ensures consistent Cas9 expression, allowing for more reliable and efficient gene editing compared to traditional transient transfection methods. Additionally, this stable cell line eliminates the need for continuous transfection of cells with Cas9, increasing the efficiency and cost savings of genome editing experiments.